BUSINESS

• Shionogi Kicks Off Global PEP Study of Xocova; NDA for Full Approval Filed in Japan
  June 12, 2023

• Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
  June 12, 2023

• ASKA, RaQualia Wind Up Ion Channels Collab
  June 12, 2023

• FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
  June 12, 2023

• AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
  June 9, 2023

• Ceolia Pharma’s Comlex Otic Solution Now Available in Japan
  June 9, 2023

• Takeda Rolls Out Low-Dose Form of SBS Therapy Revestive in Japan
  June 9, 2023

• Lecanemab Filed for Approval in South Korea: Eisai/Biogen
  June 9, 2023

• Astellas Grabs Rights to Kate’s XLMTM Gene Therapy
  June 9, 2023

• Opdivo Top-Seller Drug in Japan for 17 Months on End: Encise
  June 8, 2023

• Japan Ethical Drug Sales Up 1.4% in April: Crecon
  June 8, 2023

• Enhertu Nets Favorable Data in Pan-Tumor Trial for HER2 Solid Cancers
  June 7, 2023

• Positive PIb Data Unveiled for TROP2 ADC Plus Keytruda: Daiichi Sankyo/AZ
  June 7, 2023

• Mounjaro, Dayvigo Again Top Sales Rep Promotion Rankings for GPs, HPs in April
  June 7, 2023

• Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
  June 6, 2023

• Japan Approves 1st Gene Panel Testing for IRD
  June 6, 2023

• Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
  June 6, 2023

• Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
  June 6, 2023

• Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
  June 6, 2023

• Gilead Files HIV Med Lenacapavir in Japan
  June 5, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 142
• 143
• 144
• 145
• 146
• 147
• 148
• 149
• 150
• …
• Next ›
• 最終 »